To meet a broad range of skin health needs, Galderma offers a range of leading medical and consumer skin health brands, through three strategic areas: Prescription, Aesthetics and Consumer.
7 innovation areas
We focus our innovation on 7 areas: acne, rosacea, psoriasis, atopic dermatitis, skin ageing, sun protection and skin cancer.
7 manufacturing sites
In 2017, the 1,200+ employees at our 6 manufacturing sites produced 215 million units. We make 75% of our products in-house.
We operate from 50 sites in 40 countries, with our headquarters in Lausanne, Switzerland.
Sales by region
North America 49%
Sales by business
Creating shared value
We collaborate with the broad skin health community:
Industry-leading medical education with Derm101
Promoting community initiatives in dermatology
Engaging with the dermatology community
Find out about our leadership team by clicking here.
A timeline of our history
Foundation of Galderma
Galderma discovers Adapalene
First commercial operations
Launch of Acne treatment Differin
Galderma (UK) Ltd established
Acquisition of Loceryl Curanail, (developed by Roche and Nycomed)
Opening of production site in Baie d’Urfé, Canada
Licensing agreement for Metvix (pre-cancerous skin lesions and skin cancer treatment)
Opening of production site in Hortolândia, Brazil
Launch of Differin 0.3%
Launch of Epiduo
Launch of Azzalure and Restylane Injector